Key result
Shugan Jieyu capsule matches sertraline efficacy in AMI patients but causes fewer adverse events.
Why the study?
Does Shugan Jieyu capsule improve depression symptoms compared to sertraline in patients with acute myocardial infarction and depression?
RCT (n=149)
Randomized
Does Shugan Jieyu capsule improve depression symptoms compared to sertraline in patients with acute myocardial infarction and depression?
Shugan Jieyu capsule demonstrated similar efficacy to sertraline for treating depression in patients with acute myocardial infarction, but with a more favorable safety profile.
May offer a safer alternative to sertraline for post-AMI depression; extends RCT evidence for traditional Chinese medicine in cardiac settings.
Objective The aim is to comparatively study Shugan Jieyu capsule and sertraline for non-inferiority in the treatment of patients with acute myocardial infarction and depression (observing the curative effects and safety) by the randomized controlled experiment. Methods A total of 149 patients with acute myocardial infarction and depression were randomly divided into two groups, the Shugan Jieyu group (76 cases) and the sertraline group (73 cases), and received treatments for 24 weeks. Depression states were assessed by the rote diagnostic checklist, and effects were evaluated by the Hamilton depression scale. Drug safety for heart was assessed by left ventricular ejection fraction (reduced by 5%), blood pressure, heart rate, P-wave and R wave interval, Q-R-S complex wave, and corrected Q-T interval after 12 weeks of treatment. Results There were no significant differences in the effective rates of Shugan Jieyu and sertraline groups. Significantly lower adverse event rate was observed in the Shugan Jieyu group. Two groups had a similar cardiac safety. Conclusion Shugan Jieyu capsule has a reliable effect and high safety in patients with acute myocardial infarction and depression.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2016) conducted an RCT in Acute myocardial infarction and depression (n=149). Shugan Jieyu capsule vs. Sertraline was evaluated on Effective rates evaluated by the Hamilton depression scale. Shugan Jieyu capsule showed no significant difference in effective rates compared to sertraline, but had a significantly lower adverse event rate in patients with acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: